Dear Cancer Community Members,  

We're pleased to share the FDA Oncology Center of Excellence's (OCE) 2025 Annual Report, which outlines our efforts to achieve patient-centered regulatory decision-making through innovation and collaboration.  Some of last year’s important milestones for patients and caregivers included:  

• Approvals of 17 new cancer treatments  
• Approvals of 12 different drugs and biologics for pediatric patients with cancer 
• Collaboration with regulatory agencies in other countries to speed up access to new treatments 
• Continuation of OCE’s Rare Cancers Program to gather real-world experiences from patients 
• Assistance with 675 patients seeking access to experimental treatments through the FDA’s Expanded Access program 

The report also features a Director’s Message from Dr. Angelo De Claro, who became OCE Director in May 2026.  

To learn more about how we're working to improve cancer care, please read our full report: https://www.fda.gov/about-fda/oce-annual-reports/2025-oce-annual-report

Your voice matters in our work. We encourage you to stay informed and involved in the fight against cancer.